Athenex

+1 716.898.86261001 Main Street, Suite 600, Buffalo, New York, 14203

Athenex

Improving the lives of cancer patients everywhere

Athenex Announces
Strategic Pivot and Cost Savings Plan

LEARN MORE

A global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer

LEARN MORE

A deep innovative pipeline

LEARN MORE

Recent News

2023-03-20T08:00:00

Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update

2023-02-14T08:00:00

Athenex Announces a Reverse Stock Split

2023-01-03T08:00:00

Athenex Announces MHRA Decision on Oral Paclitaxel

2022-12-20T08:15:00

Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer

2022-12-16T08:00:00

Athenex Exits 503B Sterile Compounding Business

2022-11-22T10:30:00

Athenex Announces Positive Results of Special Stockholder Meeting

2022-11-21T08:00:00

Athenex Announces Closing of the Sale of its China API Business

2022-11-08T16:05:00

Athenex to Participate in the 5th Annual Evercore ISI HealthCONx Conference

2022-11-03T07:05:00

Athenex Announces Receipt of Positive Nasdaq Listing Determination

Our Science

We are focused on discovering and developing novel therapies for treating cancer and addressing unmet medical needs.

Investors

View press releases, events and presentations, and other investment information

Join Our Team

As the Company grows, we are always looking to add talented professionals to join the Athenex family.